Current perspectives on CHEK2 mutations in breast cancer

References

• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• MillerKDSiegelRLLinCCCancer treatment and survivorship statistics, 2016CA Cancer J Clin201666427128927253694
   PubMed Web of Science ®Google Scholar
• CarlsonRWAllredDCAndersonBOBreast cancer. Clinical practice guidelines in oncologyJ Natl Compr Canc Netw20097212219219200416
   PubMed Web of Science ®Google Scholar
• MagniMRuscicaVBuscemiGChk2 and REGgamma-dependent DBC1 regulation in DNA damage induced apoptosisNucleic Acids Res20144221131501316025361978
   PubMed Web of Science ®Google Scholar
• DufaultMRBetzBWappenschmidtBLimited relevance of the CHEK2 gene in hereditary breast cancerInt J Cancer2004110332032515095295
   PubMed Web of Science ®Google Scholar
• BellDWVarleyJMSzydloTEHeterozygous germ line hCHK2 mutations in Li-Fraumeni syndromeScience199928654492528253110617473
   PubMed Web of Science ®Google Scholar
• CybulskiCHuzarskiTGorskiBA novel founder CHEK2 mutation is associated with increased prostate cancer riskCancer Res20046482677267915087378
   PubMed Web of Science ®Google Scholar
• TaHQIveyMLFriersonHFJrCheckpoint kinase 2 negatively regulates androgen sensitivity and prostate cancer cell growthCancer Res201575235093510526573794
   PubMed Web of Science ®Google Scholar
• CybulskiCGorskiBHuzarskiTCHEK2 is a multiorgan cancer susceptibility geneAm J Hum Genet20047561131113515492928
   PubMed Web of Science ®Google Scholar
• HavranekOKleiblovaPHojnyJAssociation of germline CHEK2 gene variants with risk and prognosis of non-Hodgkin lymphomaPLoS One20151010e014081926506619
   PubMed Web of Science ®Google Scholar
• PalmeroEIAlemarBSchuler-FacciniLScreening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern BrazilGenet Mol Biol201639221022227223485
   PubMed Web of Science ®Google Scholar
• SchmidtMKHogervorstFvan HienRAge- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriersJ Clin Oncol201634232750276027269948
   PubMed Web of Science ®Google Scholar
• OffitKPierceHKirchhoffTFrequency of CHEK2*1100delC in New York breast cancer cases and controlsBMC Med Genet20034112529183
   PubMedGoogle Scholar
• Mateus PereiraLHSigurdsonAJDoodyMMCHEK2:1100delC and female breast cancer in the United StatesInt J Cancer2004112354154315382084
   PubMed Web of Science ®Google Scholar
• AbudJKoehler-SantosPAshton-ProllaPProllaJCCHEK2 1100DELC germline mutation: a frequency study in hereditary breast and colon cancer Brazilian familiesArq Gastroenterol201249427327823329222
   PubMedGoogle Scholar
• ThirthagiriECheongLSYipCHTeoSHCHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in MalaysiaFam Cancer20098435535819399639
   PubMed Web of Science ®Google Scholar
• LaitmanYKaufmanBLahadELPapaMZFriedmanEGermline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancerIsr Med Assoc J200791179179618085035
   PubMed Web of Science ®Google Scholar
• JekimovsCRChenXArnoldJLow frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individualsBr J Cancer200592478479015700044
   PubMed Web of Science ®Google Scholar
• ChekmariovaEVSokolenkoAPBuslovKGCHEK2 1100delC mutation is frequent among Russian breast cancer patientsBreast Cancer Res Treat200610019910216758118
   PubMed Web of Science ®Google Scholar
• OsorioARodriguez-LopezRDiezOThe breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer populationInt J Cancer20041081545614618615
   PubMed Web of Science ®Google Scholar
• RashidMUJakubowskaAJustenhovenCGerman populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancerEur J Cancer200541182896290316239104
   PubMed Web of Science ®Google Scholar
• MargolinSEibergHLindblomABisgaardMLCHEK2 1100delC is prevalent in Swedish early onset familial breast cancerBMC Cancer2007716317705858
   PubMed Web of Science ®Google Scholar
• Naslund-KochCNordestgaardBGBojesenSEIncreased risk for other cancers in addition to breast cancer for CHEK2*1100delC het-erozygotes estimated from the Copenhagen General Population StudyJ Clin Oncol201634111208121626884562
   PubMed Web of Science ®Google Scholar
• CaiZChehabNHPavletichNPStructure and activation mechanism of the CHK2 DNA damage checkpoint kinaseMol Cell200935681882919782031
   PubMed Web of Science ®Google Scholar
• MuranenTABlomqvistCDorkTPatient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association ConsortiumBreast Cancer Res20161819827716369
   PubMed Web of Science ®Google Scholar
• KilpivaaraOVahteristoPFalckJCHEK2 variant I157T may be associated with increased breast cancer riskInt J Cancer2004111454354715239132
   PubMed Web of Science ®Google Scholar
• LiuCWangYWangQSWangYJThe CHEK2 I157T variant and breast cancer susceptibility: a systematic review and meta-analysisAsian Pac J Cancer Prev20121341355136022799331
   PubMedGoogle Scholar
• CybulskiCGorskiBHuzarskiTEffect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutationsJ Med Genet200946213213518930998
   PubMed Web of Science ®Google Scholar
• BalochAHKhosaANBangulzaiNNovel nonsense variants c.58C>T (p.Q20X) and c.256G>T (p.E85X) in the CHEK2 gene identified in breast cancer patients from BalochistanAsian Pac J Cancer Prev20161731089109227039729
   PubMedGoogle Scholar
• BalochAHDaudSRaheemNMissense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan originMol Biol Rep20144121103110724390236
   PubMed Web of Science ®Google Scholar
• LiuYLiaoJXuYA recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese womenHum Mutat20113291000100321618645
   PubMed Web of Science ®Google Scholar
• WasielewskiMHanifi-MoghaddamPHollestelleADeleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell linesBreast Cancer Res Treat2009113228529118297428
   PubMed Web of Science ®Google Scholar
• KnappskogSChrisantharRLokkevikELow expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancerBreast Cancer Res2012142R4722420423
   PubMed Web of Science ®Google Scholar
• LiuYXuYOuyangTAssociation between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancerBMC Cancer20151519425884806
   PubMed Web of Science ®Google Scholar
• KriegeMHollestelleAJagerASurvival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapyBr J Cancer201411151004101324918820
   PubMed Web of Science ®Google Scholar
• KriegeMJagerAHollestelleASensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriersJ Cancer Res Clin Oncol2015141101879188725958056
   PubMed Web of Science ®Google Scholar
• ChrisantharRKnappskogSLokkevikECHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancerPLoS One200838e306218725978
   PubMed Web of Science ®Google Scholar
• BaeyensAClaesKWillemsPDe RuyckKThierensHVralAChromosomal radiosensitivity of breast cancer with a CHEK2 mutationCancer Genet Cytogenet2005163210611216337852
   PubMedGoogle Scholar
• CybulskiCWokolorczykDJakubowskaARisk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancerJ Clin Oncol201129283747375221876083
   PubMed Web of Science ®Google Scholar
• SchutteMSealSBarfootRVariants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibilityAm J Hum Genet20037241023102812610780
   PubMed Web of Science ®Google Scholar
• Meijers-HeijboerHvan den OuwelandAKlijnJLow-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutationsNat Genet2002311555911967536
   PubMed Web of Science ®Google Scholar
• WeischerMBojesenSEEllervikCTybjaerg-HansenANordestgaardBGCHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controlsJ Clin Oncol200826454254818172190
   PubMed Web of Science ®Google Scholar